MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
BioAtla ROE Ratio 2011-2026 | BCAB
Annual ROE Ratio BioAtla
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 164.71 | -489.14 | -174.7 | -59.05 | -45.25 | -17.07 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 164.71 | -489.14 | -103.42 |
Quarterly ROE Ratio BioAtla
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2687.13 | -2783.73 | -2962.64 | -160.0 | -195.19 | -184.28 | -145.82 | -81.46 | -99.53 | -82.41 | -71.23 | -48.36 | -58.3 | -50.17 | -49.71 | -36.55 | -42.09 | -37.69 | -23.59 | -9.27 | -9.27 | -3.73 | -0.76 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.76 | -2962.64 | -427.08 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.14 | 0.36 % | $ 443 M |  USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 8.41 | 4.73 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
-36.9 | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.83 | 0.85 % | $ 3.03 B | USA |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
BioCardia
BCDA
|
-919.33 | $ 1.2 | -0.04 % | $ 8 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
18.68 | $ 9.6 | 6.37 % | $ 1.98 B | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 9.48 | -3.27 % | $ 613 M | USA |
 |
BioVie
BIVI
|
-92.27 | $ 1.45 | 2.09 % | $ 2.14 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-136.27 | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 56.49 | 1.78 % | $ 10.8 B | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 92.3 | 1.23 % | $ 27.2 B | Germany |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-48.89 | $ 3.04 | 1.54 % | $ 259 M | USA |
 |
BioXcel Therapeutics
BTAI
|
73.22 | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 4.54 | 9.54 % | $ 683 M | Britain |
 |
Cabaletta Bio
CABA
|
-149.8 | $ 3.2 | 7.94 % | $ 322 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 3.21 | 4.56 % | $ 6.98 B | Israel |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
9.32 | $ 19.97 | 2.94 % | $ 1.78 B | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Codexis
CDXS
|
-87.03 | $ 1.97 | 7.97 % | $ 172 M | USA |
 |
Cerus Corporation
CERS
|
-24.33 | $ 1.91 | 2.42 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
-53.8 | $ 15.4 | 6.72 % | $ 928 M | USA |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.75 | 0.87 % | $ 205 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |